SNK-396
/ SynerK
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 21, 2024
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
(clinicaltrials.gov)
- P1 | N=41 | Completed | Sponsor: Syneos Health | Recruiting ➔ Completed | N=128 ➔ 41 | Trial completion date: Oct 2024 ➔ Feb 2024 | Trial primary completion date: Oct 2024 ➔ Feb 2024
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Dyslipidemia
June 09, 2023
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
(clinicaltrials.gov)
- P1 | N=128 | Recruiting | Sponsor: Syneos Health
New P1 trial • Dyslipidemia
1 to 2
Of
2
Go to page
1